New Search

If you are not happy with the results below please do another search

34 search results for: INNA-051

2

ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

Melbourne, Australia, 29 January 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, today announces it has dosed the first participants in its Phase II community study of INNA-051, with the first participant dosing now completed. INNA-051 is a virus-agnostic, once-weekly, dry […]

3

ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

Melbourne, Australia, 22 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing. The Company welcomed new investment from the Gates Foundation and the previously announced contribution from Flu […]

4

ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer

Melbourne, Australia, 6 May 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny Simmen PhD and Alison Humbles PhD as Strategic Advisors. Dr Simmen and Dr Humbles bring decades of experience gained in big pharma, specifically […]

5

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine Melbourne, Australia, 9 April 2025 – ENA Respiratory, a clinical-stage pharmaceutical company […]

6

ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults

Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased important antiviral host-defence pathways Pre-clinical data demonstrated reduced influenza virus dissemination to the lungs of aged mice, consistent with results from studies in […]

7

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a US$5 million investment from Flu Lab. Flu Lab, a California-based organization founded to advance innovative approaches for the prevention and treatment of influenza, […]

10

ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research

Publication comes as the prevalence of respiratory infections continues to rise worldwide Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces today the publication of an invited review of the preclinical and clinical development […]